ANI Pharmaceuticals (ANIP) said Friday that the US Food and Drug Administration has now approved Iluvien to treat chronic non-infectious uveitis affecting the eye's posterior segment.
The company intends to market the implant for chronic NIU-PS in addition to its current indication of diabetic macular edema in the US.
ANI shares were up 1.1% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.